share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K：重大事件
美股SEC公告 ·  06/14 05:09

Moomoo AI 已提取核心信息

TransCode Therapeutics, Inc. held its 2024 Annual Meeting of Stockholders on June 13, 2024, where several key proposals were voted upon. The meeting saw the election of four directors, Philippe P. Calais, PhD, Thomas A. Fitzgerald, Erik Manting, PhD, and Magda Marquet, PhD, each for a one-year term. Additionally, stockholders approved an amendment to increase the number of shares available under the company's 2021 Stock Option and Incentive Plan by 3,000,000 shares. The appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. However, the proposal for a reverse stock split of common stock by a ratio between 1-for-2 and 1-for-40 was not approved. An adjournment proposal was passed in case there were insufficient votes to approve the reverse stock split or the stock plan amendment, but it was not needed as the latter was approved. The total number of shares entitled to vote was 6,108,053, with 2,392,577 shares present or represented by proxy.
TransCode Therapeutics, Inc. held its 2024 Annual Meeting of Stockholders on June 13, 2024, where several key proposals were voted upon. The meeting saw the election of four directors, Philippe P. Calais, PhD, Thomas A. Fitzgerald, Erik Manting, PhD, and Magda Marquet, PhD, each for a one-year term. Additionally, stockholders approved an amendment to increase the number of shares available under the company's 2021 Stock Option and Incentive Plan by 3,000,000 shares. The appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. However, the proposal for a reverse stock split of common stock by a ratio between 1-for-2 and 1-for-40 was not approved. An adjournment proposal was passed in case there were insufficient votes to approve the reverse stock split or the stock plan amendment, but it was not needed as the latter was approved. The total number of shares entitled to vote was 6,108,053, with 2,392,577 shares present or represented by proxy.
TransCode Therapeutics，Inc.于2024年6月13日举行了其2024年股东年度大会，讨论了几项关键提案。大会选举了四位董事，分别是Philippe P. Calais, PhD，Thomas A. Fitzgerald，Erik Manting, PhD和Magda Marquet, PhD，任期为一年。此外，股东们批准了一项建议，将公司2021年股票期权和激励计划下的可用股票数量增加300万股。WithumSmith+Brown，PC被任命为独立注册会计师事务所，负责2024年12月31日结束的财政年度。然而，建议按1:2至1:40之间的比例进行普通股逆向拆分并未获得通过。通过了推迟提案，以防止无法通过普通股逆向拆分或股票计划修正案的情况下所需的投票不足，但实际上并不需要，因为后者获得了批准 。有表决权的股份总数为6,108,053股，其中有2,392,577股出席或代表投票。
TransCode Therapeutics，Inc.于2024年6月13日举行了其2024年股东年度大会，讨论了几项关键提案。大会选举了四位董事，分别是Philippe P. Calais, PhD，Thomas A. Fitzgerald，Erik Manting, PhD和Magda Marquet, PhD，任期为一年。此外，股东们批准了一项建议，将公司2021年股票期权和激励计划下的可用股票数量增加300万股。WithumSmith+Brown，PC被任命为独立注册会计师事务所，负责2024年12月31日结束的财政年度。然而，建议按1:2至1:40之间的比例进行普通股逆向拆分并未获得通过。通过了推迟提案，以防止无法通过普通股逆向拆分或股票计划修正案的情况下所需的投票不足，但实际上并不需要，因为后者获得了批准 。有表决权的股份总数为6,108,053股，其中有2,392,577股出席或代表投票。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间